PubRank

Kuo-Chi Cheng

Author PubWeight™ 16.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006 2.09
2 In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother 2006 0.84
3 Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. J Med Chem 2009 0.83
4 Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. J Med Chem 2009 0.82
5 Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 2006 0.82
6 Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles. J Med Chem 2010 0.82
7 A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors. J Med Chem 2012 0.82
8 The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett 2009 0.81
9 Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem 2009 0.81
10 Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. J Med Chem 2012 0.80
11 Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. J Med Chem 2009 0.80
12 The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor. Bioorg Med Chem Lett 2010 0.78
13 Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies. Bioorg Med Chem 2009 0.78
14 Ultra-performance liquid chromatography/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007 0.77
15 Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue. Bioorg Med Chem 2007 0.77
16 Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings. Bioorg Med Chem Lett 2009 0.76
17 Ultra-performance liquid chromatography/tandem mass spectrometric determination of testosterone and its metabolites in in vitro samples. Rapid Commun Mass Spectrom 2006 0.75
18 Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. J Med Chem 2006 0.75
19 Discovery of novel orally active ureido NPY Y5 receptor antagonists. Bioorg Med Chem Lett 2007 0.75
20 Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors. Bioorg Med Chem Lett 2010 0.75
21 The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification. J Pharm Biomed Anal 2009 0.75